CERO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer...

Stats
Today's Volume	74 888.00
Average Volume	1.08M
Market Cap	20.17M
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.00700 (0.51%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-25	Rolfe Lindsey	Buy	112 500	Stock Option (Right to Buy)
2024-03-25	Rapaport Robyn	Buy	112 500	Stock Option (Right to Buy)
2024-03-25	Laporte Kathleen	Buy	112 500	Stock Option (Right to Buy)
2024-03-25	Ehrlich Christopher B	Buy	572 182	Stock Option (Right to Buy)
2024-03-25	Corey Daniel	Buy	856 671	Stock Option (Right to Buy)

INSIDER POWER
-40.78
Last 45 transactions
Buy: 4 547 486 \| Sell: 11 315 598

Volume Correlation

Long: 0.04 (neutral)

Short: 0.17 (neutral)

Signal:(41.43) Neutral

CERo Therapeutics Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CERo Therapeutics Correlation - Currency/Commodity

0.71
( moderate )

0.62
( weak )

0.00
( neutral )

0.66
( moderate )

0.00
( neutral )

-0.37
( neutral )

Financial Reports:

No articles found.

CERo Therapeutics

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.